Kleemann J, Schilling B. Multicenter phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in japanese advanced melanoma patients: Immune resistance remains one of the major efforts in melanoma research. Br J Dermatol 2024 Jul 2:ljae279. doi: 10.1093.
PMID: 39164211